Table 2.

Number of recurrences and recurrence rates per 1000 person-years in relation to statin use after breast cancer surgery in postmenopausal women on AIs diagnosed in Denmark from 2007–2017

Exposure	Person-years	Recurrences	Incidence rate per 1000 person-years (95% CI)	Hazard ratio (95% CI)	Adjusted hazard ratio (95% CI)
Not exposed to CLM	45,596	610	13.38 (12.34–14.48)
CLM exposure	3231	34	10.52 (7.29–14.70)	0.75 (0.53–1.07)	0.75 (0.53–1.07)
Not exposed to statins	45,655	612	13.40 (12.36–14.51)
Statin exposure	3163	32	10.12 (6.92–14.28)	0.72 (0.50–1.03)	0.72 (0.50–1.04)
Not exposed to lipophilic statins	45,787	614	13.41 (12.37–14.51)
Lipophilic statin exposure	3041	30	9.87 (6.66–14.08)	0.70 (0.49–1.02)	0.70 (0.48–1.02)
Not exposed to simvastatins	46,506	619	13.31 (12.28–14.40)
Simvastatin exposure	2231	25	10.77 (6.97–15.90)	0.78 (0.52–1.16)	0.73 (0.48–1.10)
Not exposed to atorvastatins	48,000	639	13.31 (12.30–14.39)
Atorvastatin exposure	827	5	6.05 (1.96–14.11)	0.44 (0.18–1.05)	0.54 (0.22–1.31)

CI confidence interval, CLM cholesterol-lowering medication

Adjusted for; age at diagnosis; union for international cancer control; histological grade; adjuvant chemotherapy; type of primary surgery; radiotherapy; hormone therapy; metformin; aspirin